CorMedix CRMD DefenCath — Total Revenue

Other product segments

Similar metrics at other companies

IBRXOther revenues — Total Revenue

$39K+388%

MARNet fee revenues — Total Revenue

$1.4B+12.1%

BIIBMS Product Revenues — Total Revenue

$963.3M-13.0%

PTH

PTHSNet product revenues — Total Revenue

$10.67M—

LTHTotal center revenue — Total Revenue

$837.4M+13.8%

IRMDTotal devices revenue — Total Revenue

$15.39M+18.7%

FAQ

What is CorMedix's defencath — total revenue?

CorMedix (CRMD) reported defencath — total revenue of $97.51M in Q1 2026.

How has CorMedix's defencath — total revenue changed year-over-year?

CorMedix's defencath — total revenue increased by 149.5% year-over-year, from $39.08M to $97.51M.

What does defencath — total revenue mean?

This metric represents the total gross revenue generated from the commercial sale of the company's primary therapeutic product, DefenCath. It serves as a key indicator of market adoption, commercial traction, and the effectiveness of the company's go-to-market strategy for its lead asset. Tracking this revenue stream is essential for evaluating the company's transition from a development-stage entity to a commercial-stage biopharmaceutical business.